Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus sacituzumab govitecan versus pembrolizumab alone as first-line treatment for PD-L1-high metastatic non-small cell lung cancer
CTR20223405Phase 3Terminated
- Sponsor
- MSD
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, sacituzumab govitecan in non-small cell lung cancer (NSCLC), sponsored by MSD. Started Mar 2023; status: terminated.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223405.